Get the Stockscreener App
11.31
0.35%
0.04
Pre-market:
11.37
0.06
+0.53%
Telix Pharmaceuticals Ltd Adr stock is traded at $11.31, with a volume of 830.21K.
It is up +0.35% in the last 24 hours and down -3.17% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$11.27
Open:
$11.29
24h Volume:
830.21K
Relative Volume:
3.68
Market Cap:
$3.84B
Revenue:
$804.63M
Net Income/Loss:
$-7.13M
P/E Ratio:
-536.02
EPS:
-0.0211
Net Cash Flow:
$-73.42M
1W Performance:
-9.56%
1M Performance:
-3.17%
6M Performance:
+28.96%
1Y Performance:
+10.77%
1-Day Range:
$11.11
$11.38
1-Week Range:
$10.76
$12.80
52-Week Range:
$6.28
$13.11
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
11.31 | 3.84B | 804.63M | -7.13M | -73.42M | -0.0211 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
Why is Telix Pharmaceuticals stock rallying today? By Investing.com - Investing.com Canada
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse - GlobeNewswire Inc.
Telix Pharmaceuticals stock price target maintained at $20 by H.C. Wainwright - Investing.com Australia
ASX biotech expands diagnostics portfolio after FDA approval - Morningstar Australia
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD - investing.com
Two New York conferences will include Telix presentations - Stock Titan
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway - finance.yahoo.com
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock jumps on trial completion, FDA path - Investing.com
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on trial completion - Investing.com UK
Up to 75% of prostate biopsies are negative. Telix enrolled 350 patients. - Stock Titan
Earnings call transcript: Telix H1 2026 profit jumps as guidance holds - Investing.com
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) on Investors' Radar Despite a 30% One-Year Decline? - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
Telix Pharmaceuticals Limited Sponsored ADR Actuals & Estimates (NASDAQ:TLX) - TradingView
Telix webinar spotlights glioblastoma care and theranostics next week - Stock Titan
ASX Healthcare Sector Rally: CSL, ResMed and Telix Advance on Broad Market Strength - Kalkine
AI-enhanced cancer scans: Telix and United Imaging team up on theranostics - Stock Titan
Prostate cancer trial: Telix therapy shows acceptable safety in combo treatment - stocktitan.net
Telix CEO lines up back-to-back investor talks in Chicago and New York - stocktitan.net
TLX - Finviz
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals Ltd stock (AU000000TLX2): FDA filing advances - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Prostate cancer imaging tie-up aims to cut incontinence, impotence risks - Stock Titan
Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision? - Kalkine
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
Kidney cancer scan showed 98% positive predictive value in analysis - stocktitan.net
Europe begins 210-day review of Telix brain cancer imaging candidate - Stock Titan
Telix reports dosimetry data for prostate cancer therapy candidate - Investing.com
Wedge UpStock ScreenerCharts - Finviz
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):